Nuvectis Pharma, Inc.
No SEC Form 4 filings for $NVCT in the last 30 days.
Nuvectis Pharma (NASDAQ:NVCT) saw its shares climb 6.3% to $9.65 on Tuesday, with a significant increase in trading volume. Despite missing analyst EPS estimates, the clinical-stage biotech maintains a MarketBeat consensus of "Moderate Buy" with an average price target of $15.33, indicating potential for growth. Institutional investors have also recently increased their holdings in the company.
Fort Lee, NJ, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Nuvectis Pharma, Inc. ( NASDAQ: NVCT ) ( "Nuvectis" or the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...
• The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to ...
